What medical technology company announced the acquisition of Penumbra for $14.5 billion in January 2026?

In January 2026, medical technology giant Boston Scientific announced its intention to acquire Penumbra for a substantial $14.5 billion. This significant transaction immediately positioned Boston Scientific as the correct answer for the company making this major strategic move. The deal, valued at $374 per share, was structured as a mix of cash and stock, reflecting Boston Scientific's commitment to expanding its portfolio.

Penumbra, a California-based medical device manufacturer, specializes in innovative products for neurovascular and peripheral thrombectomy, which involve removing blood clots from vessels. This acquisition allows Boston Scientific to re-enter and significantly scale its presence in fast-growing segments within the vascular space, including mechanical thrombectomy and neurovascular markets, which it had previously exited in 2011. For Boston Scientific, this move is a strategic play to enhance its cardiovascular offerings and address the increasing prevalence of vascular diseases globally.

The acquisition of Penumbra by Boston Scientific is one of the largest in the medical technology sector for 2026, highlighting a trend of major players making substantial investments to gain a foothold in high-growth clinical areas. Such mergers and acquisitions are often driven by the desire to expand product portfolios, leverage new technologies, and ultimately reach more patients with advanced medical solutions. This particular deal is expected to close in 2026, pending shareholder approval and other customary closing conditions.